Pharmala Biotech【MDMA】銘柄情報

Pharmala Biotech Holdings Inc (MDMA) 銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

0.15

( - )

買値

0.145

売値

0.15

出来高

0.00 日の範囲 0.00

0.085 52 週間の範囲 0.195

時価総額

16.333M

前日終値

0.15

始値

時刻

0.16

最終取引時間

22:30:00

財務取引量

VWAP

平均取引量 (3 か月)

$ 202,083

発行済株式数

108,887,215

配当利回り

PER

-10

1 株当たり利益 (EPS)

-0.02

歳入

889.57k

純利益

-1.63M

Pharmala Biotech Holdings Inc., a biotechnology company, engages in the development, manufacture, and sale of MDMA and MDXX class molecules in service to the burgeoning clinical research community. It offers its MDMA drug active pharmaceutical ingredients under the LaNeo brand. The company is headqu... Pharmala Biotech Holdings Inc., a biotechnology company, engages in the development, manufacture, and sale of MDMA and MDXX class molecules in service to the burgeoning clinical research community. It offers its MDMA drug active pharmaceutical ingredients under the LaNeo brand. The company is headquartered in Vancouver, Canada. 詳細を表示

セクター

Healthcare

業界

Biotechnology & Life Sciences

ウェブサイト

pharmala.ca

本社

Vancouver, Canada

設立

Pharmala Biotech Holdings Inc is listed in the Healthcare sector of the Canadian Securities Exchange with ticker MDMA. The last closing price for Pharmala Biotech was $0.15. Over the last year, Pharmala Biotech shares have traded in a share price range of $ 0.085 to $ 0.195.

Pharmala Biotech currently has 108,887,215 shares in issue. The market capitalisation of Pharmala Biotech is $16.33 million. Pharmala Biotech has a price to earnings ratio (PE ratio) of -10.00.

PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 Million

TORONTO, May 20, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA; OTCQB: MDXXF...

Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech

Transaction Positions JUNS at the Forefront of Next-Generation MDMA-Based Therapeutics Following President...

PharmAla Biotech Executes Definitive Agreement to Form Special Purpose Vehicle, Restora Neurosciences, for Clinical Development of Patented Novel MDXX Molecule APA-01

TORONTO, May 13, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTCQB: MDXXF...

PharmAla Executes Binding Letter of Intent for Formation of Special Purpose Vehicle to Develop Patented Novel MDXX Molecule APA-01

TORONTO, April 27, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF...

PharmAla Issues Q2 Financial Statements and Grants Options

TORONTO, April 21, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”...

PharmAla Biotech Positioned to Supply U.S. Expanded Access Pathway for MDMA Established by Presidential Executive Order

TORONTO, April 20, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF...

Cortexa Advances Commercialisation of MDMA Supply in Australia

MELBOURNE, Australia, March 23, 2026 (GLOBE NEWSWIRE) -- Cortexa (Cortexa or the Company), a leading...

PharmAla Signs Supply & Data Agreement with Nautilus Sanctuary for Phase 2 MDMA Clinical Trial Treating Post-Traumatic Stress and Adjustment Disorder in Frontline Healthcare Workers and First Responders

TORONTO, March 03, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF), a...

PharmAla Signs Drug Donation Agreement for MDMA-Assisted Therapy Clinical Trial in Fibromyalgia

TORONTO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF), a...

PharmAla To Supply Amsterdam UMC with LaNeo™ MDMA, Including Development of New Single-Capsule Stability Data

TORONTO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF), a...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0.005	3.44827586207	0.145	0.16	0.145	72462	0.15472312	CS
4	0	0	0.15	0.195	0.13	178997	0.15811791	CS
12	0.035	30.4347826087	0.115	0.195	0.085	216598	0.15847663	CS
26	0.03	25	0.12	0.195	0.085	166696	0.13844295	CS
52	0.045	42.8571428571	0.105	0.195	0.085	177901	0.12686634	CS
156	-0.11	-42.3076923077	0.26	0.425	0.065	330725	0.18985978	CS
260	-0.29	-65.9090909091	0.44	0.54	0.02	440962	0.18488797	CS